Researchers are expanding the clinical development of a new oral medication, ABI-6250, which targets chronic hepatitis delta virus (HDV) infections and is also being tested for two liver diseases: primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Currently, there are limited treatment options for PSC, and many people with PBC do not respond well to existing therapies. This new drug aims to address these gaps by inhibiting a specific protein that plays a key role in bile acid transport and HDV entry into liver cells.

This development is significant for individuals dealing with these chronic liver conditions. PBC and PSC can lead to severe symptoms like fatigue and itching, and they may progress to more serious liver damage over time. The introduction of ABI-6250 could potentially improve liver health and quality of life for those affected, especially for the many who have not found relief with current treatments. The upcoming Phase 2 trials will further explore its effectiveness in these populations.

The evidence supporting ABI-6250 is still in its early stages. It has completed a Phase 1a trial in healthy participants, but its safety and efficacy for PBC and PSC have not yet been established. The company plans to begin Phase 2 trials in late 2026 and early 2027, depending on regulatory feedback. While the initial findings are promising, it’s important to remember that this drug is still investigational and has not been approved for use.

For now, if you or someone you know is struggling with PBC or PSC, staying informed about new treatments like ABI-6250 is essential. Discussing these developments with a healthcare provider can help you understand your options and any potential participation in clinical trials.

Source: globenewswire.com